Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 608

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 608
---
 as the surviving company of the Longevity Merger. Following the Mergers, each of Longevity and Denali will be a subsidiary of New PubCo, and New PubCo will become a publicly traded company. New PubCo is expected to change its name to Longevity Biomedical, Inc.

As part of the Business Combination, the Merger Agreement provides that the following transactions will occur:

| ● | Each                                                                                          
 share of Longevity common stock (including shares issued in connection with the Acquisition   
 Transactions and the conversion of certain Longevity indebtedness) issued and outstanding     
 will be converted into the right to receive one share of New Pubco common stock in accordance 
 with the terms of the Merger Agreement.                                                       |
| ● | Each                                                                                          
 Target Company stock option that is unexercised and outstanding at the effective time of      
 the Business Combination shall be converted into a New Pubco stock option in accordance with  
 the terms of the Merger Agreement.                                                            |
| ● | Each                                                                                          
 Target Company warrant, to the extent not previously exercised in accordance with its terms,  
 will be assumed by New Pubco.                                                                 |
| ● | Each                                                                                          
 Denali common share issued and outstanding and not otherwise redeemed will be converted into  
 the right to receive one share of New Pubco common stock in accordance with the terms of      
 the Merger Agreement.                                                                         |
| ● | Each                                                                                          
 Denali warrant will be assumed by New Pubco.                                                  |

| F-88 |

aegeria soft tissue llc

notes to the financial statements

December 31, 2023 and 2022

The consummation of the Merger Transactions are subject to the satisfaction or waiver of certain customary closing conditions contained in the Merger Agreement, including, among other things, (i) requisite approval by Denali’s shareholders, (ii) New Pubco having at least $5,000,001 of net tangible assets remaining following the closing of the Business Combination, and (iii) aggregate unrestricted cash proceeds of $30,000,000 to fund the balance sheet of New PubCo, after giving effect to the payment of Denali’s and Longevity’s transaction expenses and the closing of the Acquisition Transactions.

On August 29, 2023, the Company signed a waiver to the minimum aggregate unrestricted cash proceeds of $30,000,000 to fund the balance sheet.

The parties to the Merger Agreement have made customary representations and warranties, and have agreed to certain customary covenants including, among others